Susquehanna International Group, LLP Virios Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$0.18 - $0.58 $7,673 - $24,724	42,628 Added 182.46%	65,991 $14,000
Q1 2024 May 07, 2024	BUY	$0.31 - $0.84 $7,242 - $19,624	23,363 New	23,363 $11,000
Q3 2023 Nov 14, 2023	BUY	$0.86 - $2.42 $43,282 - $121,793	50,328 Added 95.61%	102,967 $94,000
Q2 2023 Aug 11, 2023	SELL	$0.35 - $1.94 $38,210 - $211,793	-109,172 Reduced 67.47%	52,639 $72,000
Q1 2023 May 16, 2023	BUY	$0.24 - $0.44 $38,834 - $71,196	161,811 New	161,811 $59,000
Q2 2022 Aug 15, 2022	BUY	$3.31 - $4.89 $17,926 - $26,484	5,416 Added 31.01%	22,880 $97,000
Q1 2022 May 16, 2022	BUY	$4.48 - $6.92 $78,238 - $120,850	17,464 New	17,464 $78,000

1.12M

Ticker VIRI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,330,400
Market Cap $81.4M
Description
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.